Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877929 · ClinicalTrials.gov registry record · Phase 3
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT00877929 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 706 participants.
The verdict
NCT00877929, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.
Interventions
- DRUG Telmisartan 80
- DRUG Amlodipine 10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877929
The ClinicalTrials.gov registry entry for NCT00877929 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telmisartan 80 is the first listed.
NCT00877929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877929 about?
NCT00877929 is a clinical study titled "Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus". To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.
What is the current status of trial NCT00877929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00877929?
The interventions under investigation include: Telmisartan 80 (DRUG), Amlodipine 10 (DRUG).
Who is sponsoring clinical trial NCT00877929?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.